92367-50-5

Usage

Uses

Used in Pharmaceutical Industry:
N-methyl-1-(3-methylbenzofuran-2-yl)methanamine is used as a reagent in the preparation of spiro-naphthyridinone piperidines. These compounds are known to be inhibitors of Staphylococcus aureus and Escherichia coli FabI, which are essential enzymes in the bacterial fatty acid synthesis pathway. By inhibiting these enzymes, spiro-naphthyridinone piperidines can effectively combat bacterial infections caused by these pathogens.

Upstream product

• 2256-86-2 3-methyl-1-benzofuran-2-carbonyl chloride 
• 24673-56-1 3-methyl-1-benzofuran-2-carboxylic acid 
• 74-89-5 methylamine 
• 1199-07-1 3-methylbenzofuran-2-carboxaldehyde 
• 52819-45-1 N,3-dimethylbenzofuran-2-carboxamide 

Downstream Products

• 1047981-31-6 (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide p-toluenesulfonate 
• 1047981-43-0 (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide benzenesulfonate 

Relevant academic research and scientific papers

ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS

Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.

PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE

In part, the present disclosure is directed to derivatives of (E)-N-methy1-N-(( 3-methylta 1,8-naphthyndin-3-y1)acrylamide compounds with significant solubility, solid state stability and bioavailability profiles. Said compounds have been found to be effective inhibitors of bacterial fatty acid metabolism via the effective inhibition of FabL hi addition, certain compounds are shown to be stable towards gamma radiation sterilization treatments, and are thus well-suited to the production of a sterile formulation for use in the treatment of illnesses caused by bacterial infections.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial Fab I and can be used for the treatment of Staphylococcal infections.

SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS

Salts of compounds according to formula (I) wherein the X is selected from the group consisting of H2SO4, HSO3R', HSO3Ar, H3PO4, HCl, HBr, CF3CO2H and CCl3C

HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY

In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.